• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Nanoparticles based on retinoic acid caped with ferrocenium: a novel synthesized targetable nanoparticle both with anti-cancer effect and drug loading capacity
【24h】

Nanoparticles based on retinoic acid caped with ferrocenium: a novel synthesized targetable nanoparticle both with anti-cancer effect and drug loading capacity

机译：基于视黄酸的二茂铁骨架包覆的纳米粒子：具有抗癌作用和载药量的新型合成靶向纳米粒子

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To date, there is an urgent need for cancer treatment to improve in many ways in order to successfully cure all cancers. Retinoic acid (RA) is a promising anti-cancer drug through influencing cancer stem cells (CSCs). Taxol is a chemotherapy drug for many cancers. To increase the anti-cancer effects of RA and taxol, we created a novel RA nanoparticle, FCRAN, which has the ability of carrying a second anti-cancer drug, taxol, using nanotechnological methods. The results of this study demonstrated that this RA nanoparticle was water-soluble and retained the same effects as RA on cancer cells, such as inhibiting the proliferation of CSCs, inducing the differentiation of CSCs, and enhancing the sensitivity of CSCs to chemotherapeutic drugs. In addition, this RA nanoparticle can be used to carry a second anticancer drug, taxol, to become FCRAN/T and synergistically enhance the anti-cancer effects of both drugs in vivo . Interestingly, the FCRAN/T is a targetable anti-cancer nanoparticle in the presence of higher levels of glutathione (GSH) in cancer cells. Our results demonstrate that our novel synthesized nanoparticles not only retain the RA functions, but can also carry a second anticancer drug to play a synergistic anticancer role with good water solubility, in particular FCRAN/T can target cancer cells. Therefore, our novel synthesized targetable anti-cancer nanoparticles have a better application prospect than that of RA or taxol alone.
机译：迄今为止，迫切需要以多种方式改善癌症治疗以成功治愈所有癌症。维甲酸（RA）通过影响癌症干细胞（CSC）是一种有前途的抗癌药物。紫杉酚是许多癌症的化学治疗药物。为了增加RA和紫杉醇的抗癌作用，我们创建了一种新颖的RA纳米颗粒FCRAN，它具有使用纳米技术方法携带第二种抗癌药物紫杉醇的能力。这项研究的结果表明，这种RA纳米颗粒是水溶性的，并保留了与RA相同的癌细胞作用，例如抑制CSCs的增殖，诱导CSCs的分化以及增强CSCs对化疗药物的敏感性。另外，该RA纳米颗粒可用于携带第二种抗癌药物紫杉酚，以变为FCRAN / T，并在体内协同增强两种药物的抗癌作用。有趣的是，在癌细胞中存在较高水平的谷胱甘肽（GSH）的情况下，FCRAN / T是可靶向的抗癌纳米颗粒。我们的结果表明，我们新颖的合成纳米颗粒不仅保留了RA功能，而且还可以携带第二种抗癌药物，以良好的水溶性发挥协同抗癌作用，尤其是FCRAN / T可以靶向癌细胞。因此，我们新型合成的靶向抗癌纳米粒子比单独使用RA或紫杉醇具有更好的应用前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号